PETALUMA, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced financial results for the first fiscal quarter, ended June 30, 2017.
Total revenue was $3.8 million for the first quarter as compared to $2.6 million for the same period last year. Product revenues of $3.6 million were up 49%, or $1.2 million, when compared to the same period last year, driven by strong growth in the U.S. and international markets. The numbers in this press release reflect the reclassification of the financial components of the Latin American operations as a discontinued business due to the sale of this business in October 2016.
